We found that PD-L1 is constitutively expressed on both tumor (CD45−) and immune cells (CD45+), but the frequency of 4MOSC1 tumor cells that expressed PD-L1 was much higher than the frequency of 4MOSC2 cells expressing PD-L1 (Fig. 2f). The gene discussed is PTPRC; the disease is neoplasm.